ANALISIS PASIEN CHRONIC LYMPHOCYTIC LEUKEMIA DAN DIFFUSE LARGE B-CELL LYMPHOMA (SINDROM RICHTER)
Abstract
Sindrom Richter (RS) didefinisikan sebagai transformasi agresif dari leukemia limfositik kronis (CLL) atau leukemia limfositik kecil (SLL) menjadi limfoma sel B besar yang menyebar atau limfoma Hodgkin. Beberapa faktor risiko memainkan peran penting dalam perubahan biomolekuler pada kondisi ini. Dua varian patologis RS diakui: yaitu, varian limfoma sel B besar (DLBCL) difus dan varian limfoma Hodgkin (HL) yang langka. Diagnosis RS harus didasarkan pada tanda dan gejala klinis, temuan histologis dan molekuler. Hasil RS umumnya buruk, dengan tingkat remisi lengkap hanya 20% dan kelangsungan hidup jangka panjang kurang dari 20% dengan kemoterapi. Kemoterapi kombinasi yang mengandung Rituximab untuk DLBCL adalah pengobatan yang paling banyak digunakan di RS tipe DLBCL. Kami melaporkan seorang wanita berusia 42 tahun dengan keluhan utama perut membesar dengan cepat dengan manifestasi pembesaran kelenjar getah bening yang progresif. Pasien didiagnosis dengan sindrom Richter tipe DLBCL. Dia telah diberikan kemoterapi dan dikategorikan sebagai pasien risiko tinggi dengan prognosis buruk.
References
Agbay, R. L., Jain, N., Loghavi, S., Medeiros, L. J., & Khoury, J. D. (2016). Histologic Transformation of Chronic Lymphocyttic Leukemia/Small Lymphocytic Lymphoma. American Journal of Haematology, 91(10): 1036-1043.
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, Tresckow J, Eichhorst B. Richter Transformation in Chronic Lympocytic Leukemia (CLL) – A Pooled Analysis of German CLL Study Group (GCLLSG) Front Line Treatment Trials. Leukemia. 2020; 35(1):169-176.
Andrea, I., Silvia, D., & Tizziana, V. (2022). Novel Approaches for the Treatment of Patients with Richter’s Syndrome. Current Treatment Option in Oncology, 23:526-542.
Ben-Dali, Y., Hleuhel, M. H., Andersen, M. A., Brieghel, C., Clasen-Linde, E., Da Cunha-Bang, C., & Niemann, C. U. (2018). Risk Factors Associated with Richter's Transformation in Patients with Chronic Lymphocytic Leukemia. Blood, 132, 1697.
Broséus, J., Hergalant, S., Vogt, J., Tausch, E., Kreuz, M., Mottok, A., ... & Stilgenbauer, S. (2023). Molecular Characterization of Richter Syndrome Identifies De Novo Diffuse Large B-cell Lymphomas with Poor Prognosis. Nature Communications, 14(1), 309.
Condoluci, A., & Rossi, D. (2021). Richter Syndrome. Current Oncology Reports, 23, 1-10.
Condoluci, A., & Rossi, D. (2022). Biology and Treatment of Richter Transformation. Frontiers in Oncology, 1065.
Elnair, R., Ellithi, M., Kallam, A., Shostrom, V., & Bociek, R. G. (2021). Outcomes of Richter’s Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Analysis of the SEER database. Annals of Hematology, 100, 2513-2519.
Eyre, T. A., & Schuh, A. (2017). An Update for Richter Syndrome–New Directions and Developments. British Journal of Haematology, 178(4), 508-520.
Giné, E., Martinez, A., Villamor, N., López-Guillermo, A., Camos, M., Martinez, D., ... & Montserrat, E. (2010). Expanded and Highly Active Proliferation Centers Identify a Histological Subtype of Chronic Lymphocytic Leukemia (“Accelerated” Chronic Lymphocytic Leukemia) with Aggressive Clinical Behavior. Haematologica, 95(9), 1526-1533.
Mouhssine, S., & Gaidano, G. (2022). Richter Syndrome: From Molecular Pathogenesis to Druggable Targets. Cancers, 14(19), 4644.
Parikh, S. A., Kay, N. E., & Shanafelt, T. D. (2014). How we treat Richter syndrome. Blood, The Journal of the American Society of Hematology, 123(11), 1647-1657.
Petrackova, A., Turcsanyi, P., Papajik, T., & Kriegova, E. (2021). Revisiting Richter Transformation in the Era of Novel CLL agents. Blood Reviews, 49, 100824.
Susanibar‐Adaniya, S., & Barta, S. K. (2021). 2021 Update on Diffuse large B cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification and Management. American Journal of Hematology, 96(5), 617-629.
Tsimberidou, A. M., O'Brien, S., Khouri, I., Giles, F. J., Kantarjian, H. M., Champlin, R., ... & Keating, M. J. (2006). Clinical Outcomes and Prognostic Factors in Patients with Richter's Syndrome Treated with Chemotherapy or Chemoimmunotherapy with or without Stem-Cell Transplantation. Journal of Clinical Oncology, 24(15), 2343-2351.
Wang, Y., Tschautscher, M. A., Rabe, K. G., Call, T. G., Leis, J. F., Kenderian, S. S., ... & Ding, W. (2020). Clinical Characteristics and Outcomes of Richter Transformation: Experience of 204 Patients from a Single Center. Haematologica, 105(3), 765.
